TY  - BOOK
AU  - Riccardi, Giovanna||Sala, Claudia
TI  - Tuberculosis Drug Discovery and Development 2019
KW  - mycobacteria||tuberculosis||multi-drug resistance||drug discovery||promiscuous targets||Mycobacterium tuberculosis||rifampin||isoniazid||mechanisms of resistance||mutations||granulomas||caseum||cell envelope||dormancy||delpazolid||macozinone||DprE1 inhibitor||clinical studies||discovery||mode of action||drug resistance||toxicity||target||energy metabolism||electron transport chain||oxidative phosphorylation||bedaquiline||Q203||MID3||pharmacokinetics||pharmacodynamics||drug-drug interactions||in vitro||in vivo||drug development||tuberculosis treatment||biomarkers||drug combination||clinical trial||BCG||tuberculosis vaccines||TBVI||EDCTP||IAVI||CTVD||host-directed therapy||anti-virulence compounds||TB||post-treatment sequelae||surgery||pulmonary rehabilitation||Carlo Forlanini||artificial pneumothorax||n/a||structure-based drug design||target-based drug design||PknB||PknG||DNA gyrase||antibiotic||mycobacterium||genomics||transcriptomics||proteomics||metabolomics||lipidomics||target identification||mechanism of action||antimicrobial drug resistance (AMR)||target-based screening||phenotypic screening||antituberculosis agents||antimycobacterial||anti-TB drug pipeline||privileged targets||lead generation
UR  - https://mdpi.com/books/pdfview/book/3124
ER  -